mRNA-1468 / Moderna - LARVOL DELTA

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age (clinicaltrials.gov) - P1 | N=659 | Terminated | Sponsor: ModernaTX, Inc. | Phase classification: P1/2 ➔ P1 | Trial completion date: Jun 2026 ➔ Dec 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Dec 2025; The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine.

First-in-human • Phase classification • Trial completion date • Trial primary completion date • Trial termination • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=659 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=657 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=507 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Jul 2024 ➔ Jun 2026 | Trial primary completion date: Jul 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=507 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2024 ➔ Jul 2024 | Trial primary completion date: Nov 2024 ➔ Jul 2024

Enrollment closed • Trial completion date • Trial primary completion date • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=500 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Herpes Zoster • Varicella Zoster

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age (clinicaltrials.gov) - P1/2 | N=500 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Herpes Zoster • Varicella Zoster

MODERNA EXPANDS ITS MRNA PIPELINE WITH THREE NEW DEVELOPMENT PROGRAMS (Moderna Press Release) - "Moderna, Inc...announced that it is expanding its mRNA pipeline with three new development programs...The development programs announced today are mRNA vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) to reduce the rate of shingles and a new checkpoint cancer vaccine."

Pipeline update • Herpes Zoster • Infectious Disease